EUDA Health Holdings Limited Announces Amendment to Streeterville Warrant Agreement

Rhea-AI Summary

EUDA Health Holdings (NASDAQ: EUDA) announced an amendment to its warrant agreement with Streeterville Capital dated December 4, 2025. The amendment reduces the Warrant exercise price from $6.00 to $4.00 and lowers the minimum closing price that triggers a Forced Exercise from $7.50 to $6.00. The original Warrant was issued for an aggregate purchase price of $100,000 and is exercisable into up to 2,000,000 ordinary shares. The Cash Exercise Period is ninety (90) days from issuance, after which Streeterville will be deemed to have made a cashless exercise at a 1-for-10 conversion if not exercised for cash.

Positive

• Exercise price reduced from $6.00 to $4.00
• Warrant covers up to 2,000,000 ordinary shares
• $100,000 aggregate purchase price for the Warrant

Negative

• Potential issuance of up to 2,000,000 ordinary shares (dilution)
• Forced Exercise threshold lowered from $7.50 to $6.00

News Market Reaction

+5.70%

9 alerts

+5.70% News Effect

+19.9% Peak in 1 hr 15 min

+$6M Valuation Impact

$112M Market Cap

0.5x Rel. Volume

On the day this news was published, EUDA gained 5.70%, reflecting a notable positive market reaction. Argus tracked a peak move of +19.9% during that session. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $6M to the company's valuation, bringing the market cap to $112M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Warrant shares: 2,000,000 ordinary shares Warrant purchase price: US$100,000 Exercise price cut: US$6.00 to US$4.00 +5 more

8 metrics

Warrant shares 2,000,000 ordinary shares Maximum shares exercisable under Streeterville warrant

Warrant purchase price US$100,000 Aggregate purchase price paid for the warrant

Exercise price cut US$6.00 to US$4.00 Amended cash exercise price per share

Forced exercise trigger US$7.50 to US$6.00 Amended minimum closing price for forced exercise

Cash exercise period 90 days Period during which warrant may be exercised for cash

Cashless ratio 1 share per 10 warrants Automatic cashless exercise ratio after cash period plus two weeks

Convertible notes capacity US$10,000,000 Maximum under prior convertible note purchase agreement

Impairment charge US$14,762,562 Impairment on CK Health-related intangible assets

Market Reality Check

Price: $1.21 Vol: Volume 61,952 is far belo...

low vol

$1.21 Last Close

Volume Volume 61,952 is far below the 20-day average 667,878, indicating muted trading ahead of this warrant amendment. low

Technical Price $2.28 is trading below the 200-day MA $2.95, reflecting a weaker longer-term trend before this news.

Peers on Argus

Peers show mixed, modest moves (e.g., OMH +2.11%, DUO +3.11%, NYC -2.75%) while ...

Peers show mixed, modest moves (e.g., OMH +2.11%, DUO +3.11%, NYC -2.75%) while EUDA was down 0.44%, suggesting stock-specific factors rather than a broad sector move.

Historical Context

5 past events · Latest: Dec 30 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 30	Stem cell platform	Positive	+0.0%	China stem cell extraction and cryostorage platform launch with partners.
Dec 29	Product upgrade	Positive	-4.5%	Announcement of EUDA Helixé 2.0 longevity supplement launch and formulation changes.
Dec 23	Clinic launch	Positive	+41.2%	Launch of comprehensive stem cell therapy platform and first Shenzhen clinic.
Dec 22	Token integration	Positive	-51.4%	Integration of QB utility token into digital health and rewards platform.
Dec 08	Token plans	Positive	+8.5%	Plans to integrate QB token and build a digital asset treasury strategy.

Pattern Detected

Recent EUDA news has produced volatile and often divergent price reactions, with some strategic announcements followed by sharp gains and others by notable selloffs or flat trading.

Recent Company History

Over the past months, EUDA announced several strategic initiatives, including QB token integration, longevity-focused stem cell platforms, and new product launches like EUDA Helixé 2.0. Price reactions ranged from -51.43% on the QB token integration to +41.18% on the Shenzhen stem cell clinic launch. The latest warrant amendment fits into an active period of capital structure and strategic ecosystem developments, following previously disclosed convertible note programs and digital health expansion.

Market Pulse Summary

The stock moved +5.7% in the session following this news. A strong positive reaction aligns with EUD...

Analysis

The stock moved +5.7% in the session following this news. A strong positive reaction aligns with EUDA’s history of sharp moves around financing and strategic announcements, as seen with prior swings of +41.18% and -51.43%. The warrant amendment, including a lower exercise price and adjusted forced exercise trigger, may have been viewed as impactful for capital structure. However, past volatility suggests that follow-through depended on subsequent execution and investor perception of dilution and growth prospects.

Key Terms

warrant, cashless exercise, forced exercise, prospectus supplement, +2 more

6 terms

warrant financial

"for the issuance of a warrant (the “Warrant”) exercisable into up to 2,000,000..."

A warrant is a time-limited financial contract that gives its holder the right to buy a company's shares at a set price before a specified date, like a coupon that lets you purchase stock at a fixed discount for a limited time. It matters to investors because warrants offer leveraged exposure to a stock’s upside and can dilute existing shareholders if exercised, so they affect potential gains and the company’s outstanding share count.

cashless exercise financial

"Streeterville Capital will automatically be deemed to have made a “cashless” exercise..."

A cashless exercise is a way for an option holder to convert stock options into actual shares without paying the purchase price in cash; instead they immediately give up a portion of the newly issued shares to cover the cost and any withholding taxes. Investors care because this process increases the number of shares available and can slightly dilute existing holdings, while also signaling how insiders or employees are realizing compensation without needing cash — similar to paying for a purchase by handing over part of what you just bought.

forced exercise financial

"required to trigger a “Forced Exercise” (defined in the Warrant) from US$7.50 to US$6.00."

Forced exercise occurs when the issuer of options or warrants compels holders to convert those instruments into shares (or pay the strike) before the planned expiry, based on contract terms that allow such early conversion. It matters to investors because it can increase the number of outstanding shares and dilute existing ownership, oblige option holders to pay cash or accept shares sooner than expected, and thereby affect a company’s share price and capital structure — like being told to redeem a coupon early, changing everyone’s stake and the company’s cash position.

prospectus supplement regulatory

"pursuant to a prospectus supplement dated December 4, 2025, as part of a registration..."

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

registration statement regulatory

"as part of a registration statement on Form F-3 (File No. 333-282723)..."

A registration statement is a formal document that companies file with a government agency to offer new shares of stock to the public. It provides essential information about the company's finances, operations, and risks, helping investors make informed decisions. Think of it as a detailed product description that ensures transparency and trust before buying into a company.

form f-3 regulatory

"registration statement on Form F-3 (File No. 333-282723), which was filed..."

Form F-3 is a U.S. securities filing that lets eligible foreign companies pre-register and then quickly sell shares or other securities to raise money, because they already meet ongoing reporting and size tests. For investors it signals that the company is up-to-date with regulatory disclosure and has an efficient way to issue new securities — similar to a pre-approved credit line — which can mean faster capital raises but also potential dilution of existing holdings.

AI-generated analysis. Not financial advice.

SINGAPORE, Jan. 07, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) “EUDA” or “the Company”, a Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that it has entered into an amendment (the “Warrant Amendment”) to its previously disclosed warrant agreement with Streeterville Capital, LLC (“Streeterville Capital”).

Background on the Original Warrant Transaction

As previously announced, on November 26, 2025, EUDA entered into a securities purchase agreement with Streeterville Capital, a Utah limited liability company, for the issuance of a warrant (the “Warrant”) exercisable into up to 2,000,000 newly issued ordinary shares of EUDA for an aggregate purchase price of US$100,000. The Warrant was issued on December 4, 2025. The offer and sale of the Warrant and the Warrant Shares were made pursuant to a prospectus supplement dated December 4, 2025, as part of a registration statement on Form F-3 (File No. 333-282723), which was filed with the Securities and Exchange Commission on October 18, 2024 and declared effective on November 4, 2024. The Warrant may be exercised for cash for ninety (90) days (unless extended by the parties) from the date of issuance (the “Cash Exercise Period”). At the end of two weeks after the Cash Exercise Period has expired, Streeterville Capital will automatically be deemed to have made a “cashless” exercise of the Warrant, and the Company will be required to issue to Streeterville Capital one (1) ordinary share for every ten (10) outstanding Warrant Shares for no additional consideration.

Summary of Amended Terms

On December 16, 2025, EUDA and Streeterville Capital entered into the Warrant Amendment to (i) reduce the exercise price of the Warrant from US$6.00 per share to US$4.00 per share and (ii) reduce the minimum closing price required to trigger a “Forced Exercise” (defined in the Warrant) from US$7.50 to US$6.00. All other terms of the warrant remain unchanged.

About EUDA Health Holdings Limited

EUDA Health Holdings Limited (NASDAQ: EUDA) is a Singapore-based leading non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia and China. The Company aims to become a market leader in non-invasive and preventive healthcare, with a strategic focus on the fast-growing longevity sector. Our mission is to address the evolving healthcare needs of over 1.8 billion people across the region which is experiencing significant demographic shifts as more than 30% of the population ages rapidly. By offering innovative, accessible, and science-backed health solutions, EUDA is positioned to lead the transformation of regional healthcare from reactive medical treatment to proactive, longevity-focused care. EUDA also runs a Singapore-based property management business.

Forward-Looking Statements

This document may contain forward-looking statements regarding risks and uncertainties. These statements usually use forward-looking words, such as the words “estimates,” “projected,” “expects,” “envisions,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions). These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside EUDA’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. You should not overly rely on forward-looking statements that are only applicable to the date of publication of this document. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Christensen Advisory
Christian Arnell
Phone: + 852 9040 0621
Email: christian.arnell@christensencomms.com

FAQ

What change did EUDA (NASDAQ: EUDA) make to the Streeterville warrant on January 7, 2026?

EUDA amended the warrant to reduce the exercise price from $6.00 to $4.00 and lower the Forced Exercise trigger from $7.50 to $6.00.

How many shares can Streeterville Capital receive from the EUDA warrant amendment?

The Warrant is exercisable into up to 2,000,000 ordinary shares of EUDA.

What was the original purchase price paid for the EUDA warrant issued to Streeterville Capital?

The aggregate purchase price for the Warrant was $100,000.

When does the Cash Exercise Period for the EUDA Warrant expire and what happens after?

The Cash Exercise Period is 90 days from issuance; after two weeks following its expiration, Streeterville is deemed to have made a cashless exercise at a 1-for-10 conversion.

How does lowering the Forced Exercise trigger affect the EUDA warrant terms dated December 4, 2025?

Lowering the Forced Exercise trigger from $7.50 to $6.00 changes the stock-price threshold that can compel exercise under the Warrant terms.